Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EcNΔlpp::A5-aTN
- Development stage
- Preclinical
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
EcNΔlpp::A5-aTN is an engineered live biotherapeutic product (LBP) derived from the probiotic *Escherichia coli* Nissle 1917 (EcN), developed for the treatment of ulcerative colitis (UC). The strain is genetically modified to surface-display Annexin A5 (ANXA5), a protein that binds to phosphatidylserine (PS) exposed on the surface of apoptotic colonic epithelial cells, thereby improving the targeting and colonization of the bacteria at sites of intestinal inflammation. To enhance therapeutic delivery, the *lpp* gene (encoding Braun's lipoprotein) is deleted to increase the secretion of an anti-TNF-α nanobody (aTN) cargo. This dual-action approach combines localized anti-inflammatory activity with improved mucosal barrier restoration and immune-microbiota balance, offering a potential alternative to systemic anti-TNF biologics with reduced side effects and improved cost-effectiveness.
- Other names
- EcN-A5-aTNEcN-A-5-aTNEcN-A 5-aTNengineered Escherichia coli Nissle 1917 Δlpp::A5-aTN
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on EcNΔlpp::A5-aTN.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EcNΔlpp::A5-aTN.